PATHWAY® HER-2/neu (4B5) Rabbit Monoclonal primary antibody

The FDA-approved Ventana PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Antibody is intended for the semi-quantitative detection of HER2 antigent in sections of formalin-fixed, paraffin-embedded normal and neoplastic tissue. Created to run on a Ventana automated immunohistochemistry slide staining device, it is indicated as an aid in the assessment of breast cancer patients for whom Herceptin treatement is considered.
PATHWAY anti-HER-2/neu is part of the Ventana rabbit monoclonal breast panel.